These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 15251371)

  • 61. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients.
    Renoult E; Clermont MJ; Phan V; Buteau C; Alfieri C; Tapiero B
    Pediatr Transplant; 2008 Jun; 12(4):420-5. PubMed ID: 18466427
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
    Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Value of a short (7 days) prophylactic course of ganciclovir in the prevention of cytomegalovirus disease after heart transplantation].
    Giménez D; María Arizón J; de la Torre J; Anguita M; Escauriaza J; López Granados A; Mesa D; Torres F; Casares J; Concha M; Vallés F
    Rev Esp Cardiol; 1996 Jan; 49(1):35-40. PubMed ID: 8685510
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Szer J; Durrant S; Schwarer AP; Bradstock KF; Gibson J; Arthur C; To LB; Hughes T; Raunow H
    Intern Med J; 2004 Mar; 34(3):98-101. PubMed ID: 15030456
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection.
    Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M
    Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
    Verma A; Devine S; Morrow M; Chen YH; Mihalov M; Peace D; Stock W; Pursell K; Wickrema A; Yassine M; Jessop E; van Besien K
    Bone Marrow Transplant; 2003 May; 31(9):813-6. PubMed ID: 12732890
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
    Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H
    Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation.
    Wiesner RH; Marin E; Porayko MK; Steers JL; Krom RA; Paya CV
    Gastroenterol Clin North Am; 1993 Jun; 22(2):351-66. PubMed ID: 8389735
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Cytomegalovirus infection in lung transplantation; current status, detection, prophylactic treatment].
    Aoe M; Tao H; Yamane M; Toyooka S; Sano Y; Okazaki M; Date H
    Kyobu Geka; 2007 Oct; 60(11):988-92. PubMed ID: 17926902
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yanada M; Yamamoto K; Emi N; Naoe T; Suzuki R; Taji H; Iida H; Shimokawa T; Kohno A; Mizuta S; Maruyama F; Wakita A; Kitaori K; Yano K; Hamaguchi M; Hamajima N; Morishima Y; Kodera Y; Sao H; Morishita Y
    Bone Marrow Transplant; 2003 Oct; 32(8):801-7. PubMed ID: 14520425
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Should recurrent Cytomegalovirus infections in patients with liver transplantation be treated?].
    Tarp BD; Astrup LB
    Ugeskr Laeger; 1997 May; 159(22):3413-6. PubMed ID: 9199030
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation.
    Macdonald PS; Keogh AM; Marshman D; Richens D; Harvison A; Kaan AM; Spratt PM
    J Heart Lung Transplant; 1995; 14(1 Pt 1):32-8. PubMed ID: 7727473
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy.
    Machado CM; Dulley FL; Boas LS; Castelli JB; Macedo MC; Silva RL; Pallota R; Saboya RS; Pannuti CS
    Bone Marrow Transplant; 2000 Aug; 26(4):413-7. PubMed ID: 10982288
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study.
    Sagedal S; Nordal KP; Hartmann A; Midtvedt K; Foss A; Asberg A; Degré M; Fauchald P; Rollag H
    Nephrol Dial Transplant; 2003 Sep; 18(9):1899-908. PubMed ID: 12937241
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cytomegalovirus viral load monitoring after allogeneic bone marrow transplantation in patients receiving antiviral prophylaxis.
    Howden BP; Michaelides A; Spelman DW; Spencer A; Schwarer AP; Wesselingh S; Kotsimbos TC
    Bone Marrow Transplant; 2003 Oct; 32(8):795-800. PubMed ID: 14520424
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Primary cytomegalovirus infection after combined cadaveric transplantation of the liver and kidney].
    Slavicek J; Puretić Z; Glavas-Boras S; Smalcelj R; Barisić I; Vuković J; Seso-Simić D; Slavicek V; Humar I; Kes P
    Acta Med Croatica; 2003; 57(1):87-90. PubMed ID: 12876872
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients.
    Brennan DC; Garlock KA; Singer GG; Schnitzler MA; Lippmann BJ; Buller RS; Gaudreault-Keener M; Lowell JA; Shenoy S; Howard TK; Storch GA
    Transplantation; 1997 Dec; 64(12):1843-6. PubMed ID: 9422429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.